Tech Company Financing Transactions

Olema Oncology Funding Round

Vivo Capital, BlackRock and BVF Partners participated in a $85 million Series C capital raise for Olema Oncology. The round closed on 10/2/2020.

Transaction Overview

Company Name
Announced On
10/2/2020
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series C
Proceeds Purpose
Olema will use the financing proceeds to advance the clinical development of OP-1250, its lead product candidate in breast cancer, and expand ongoing research and development activities.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
665 3rd St. 250
San Francisco, CA 94107
USA
Phone
Undisclosed
Email Address
Overview
Olema Oncology (Nasdaq: OLMA) is a biopharmaceutical company developing innovative targeted therapies for women's cancers. The Company's lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Profile
Olema Oncology LinkedIn Company Profile
Social Media
Olema Oncology Company Twitter Account
Company News
Olema Oncology News
Facebook
Olema Oncology on Facebook
YouTube
Olema Oncology on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Sean Bohen
  Sean Bohen LinkedIn Profile  Sean Bohen Twitter Account  Sean Bohen News  Sean Bohen on Facebook
Chief Medical Officer
Pamela Klein
  Pamela Klein LinkedIn Profile  Pamela Klein Twitter Account  Pamela Klein News  Pamela Klein on Facebook
Chief Operating Officer
Shane Kovacs
  Shane Kovacs LinkedIn Profile  Shane Kovacs Twitter Account  Shane Kovacs News  Shane Kovacs on Facebook
Chief Scientific Officer
Peter Kushner
  Peter Kushner LinkedIn Profile  Peter Kushner Twitter Account  Peter Kushner News  Peter Kushner on Facebook
Chief Technical Officer
Cyrus Harmon
  Cyrus Harmon LinkedIn Profile  Cyrus Harmon Twitter Account  Cyrus Harmon News  Cyrus Harmon on Facebook
VP - Bus. Development
Kinney Horn
  Kinney Horn LinkedIn Profile  Kinney Horn Twitter Account  Kinney Horn News  Kinney Horn on Facebook
VP - Bus. Development
David Myles
  David Myles LinkedIn Profile  David Myles Twitter Account  David Myles News  David Myles on Facebook
VP - General Counsel
John Moriarty
  John Moriarty LinkedIn Profile  John Moriarty Twitter Account  John Moriarty News  John Moriarty on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/2/2020: ScriptDrop venture capital transaction
Next: 10/3/2020: Braintrust venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary